A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation

Michael S. Garshick; Kamelia Drenkova; Tessa J. Barrett; Florencia Schlamp; Edward A. Fisher; Stuart Katz; Sanja Jelic; Andrea L. Neimann; Jose U. Scher; James Krueger; Jeffrey S. Berger

doi:10.1016/j.jid.2021.07.190

A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation

Michael S. Garshick, Kamelia Drenkova, Tessa J. Barrett, Florencia Schlamp, Edward A. Fisher, Stuart Katz, Sanja Jelic, Andrea L. Neimann, Jose U. Scher, James Krueger, Jeffrey S. Berger

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Original language	English
Pages (from-to)	1749-1752.e4
Journal	Journal of Investigative Dermatology
Volume	142
Issue number	6
DOIs	https://doi.org/10.1016/j.jid.2021.07.190
State	Published - Jun 2022
Externally published	Yes

Access to Document

10.1016/j.jid.2021.07.190

Cite this

Garshick, M. S., Drenkova, K., Barrett, T. J., Schlamp, F., Fisher, E. A., Katz, S., Jelic, S., Neimann, A. L., Scher, J. U., Krueger, J., & Berger, J. S. (2022). A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. Journal of Investigative Dermatology, 142(6), 1749-1752.e4. https://doi.org/10.1016/j.jid.2021.07.190

@article{77004fa82262482e9c5e7d2e923c4862,

title = "A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation",

author = "Garshick, \{Michael S.\} and Kamelia Drenkova and Barrett, \{Tessa J.\} and Florencia Schlamp and Fisher, \{Edward A.\} and Stuart Katz and Sanja Jelic and Neimann, \{Andrea L.\} and Scher, \{Jose U.\} and James Krueger and Berger, \{Jeffrey S.\}",

note = "Funding Information: This study was supported by a National Institutes of Health (Bethesda, MD) training grant T32HL098129; National Institutes of Health Clinical and Translational Science Award at New York University Awards UL1TR001445, KL2TR001446, and TL1TR001447; American Heart Association Career Development Grant 18CDA34080540; Dermatology Foundation Research Grant; and National Psoriasis Foundation Bridge Grant (all awarded to MSG) and American Heart Association Career Development Grant 18CDA34110203AHA and American Society of Hematology (18-A0-00-1001884) to TJB. JUS was supported, in part, by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases R01AR074500, the Riley Family Foundation, the Beatriz Snyder Foundation, the Rheumatology Research Foundation , and the National Psoriasis Foundation Diagnostic Challenge Grant. JSB was supported, in part, by the National Institutes of Health grants R01HL139909 and R35HL144993. Funding Information: MSG has received personal fees from Abbvie. JUS has served as a consultant for Janssen, Abbvie, Novartis, Sanofi, UCB, and BMS. JK has received grants from Novartis, Pfizer, Amgen, Lilly, Boehringer, Innovaderm, BMS, Janssen, Abbvie, Paraxel, Leo Pharma, Vitae, Akros, Regeneron, Allergan, Novan, Biogen MA, Sienna, UCB, Celgene, Botanix, Incyte, Avillion, and Exicure. He has received personal fees from Novartis, Pfizer, Amgen, Lilly, Boehringer, BiogenIdec, Abbvie, Leo Pharma, Escalier, Valeant, Aurigne, Allergan, Asana, UCB, Sienna, Celgene, Nimbus, Menlo, Aristea, Sanofi, Sun Pharma, Almirall, Arena, and BMS. JSB has grants from the National Institutes of Health/National Heart, Lung, and Blood Institute related to the topic and has served on the advisory board for Amgen and Jannsen. ",

year = "2022",

month = jun,

doi = "10.1016/j.jid.2021.07.190",

language = "English",

volume = "142",

pages = "1749--1752.e4",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Elsevier B.V.",

number = "6",

}

Garshick, MS, Drenkova, K, Barrett, TJ, Schlamp, F, Fisher, EA, Katz, S, Jelic, S, Neimann, AL, Scher, JU, Krueger, J & Berger, JS 2022, 'A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation', Journal of Investigative Dermatology, vol. 142, no. 6, pp. 1749-1752.e4. https://doi.org/10.1016/j.jid.2021.07.190

TY - JOUR

T1 - A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation

AU - Garshick, Michael S.

AU - Drenkova, Kamelia

AU - Barrett, Tessa J.

AU - Schlamp, Florencia

AU - Fisher, Edward A.

AU - Katz, Stuart

AU - Jelic, Sanja

AU - Neimann, Andrea L.

AU - Scher, Jose U.

AU - Krueger, James

AU - Berger, Jeffrey S.

N1 - Funding Information: This study was supported by a National Institutes of Health (Bethesda, MD) training grant T32HL098129; National Institutes of Health Clinical and Translational Science Award at New York University Awards UL1TR001445, KL2TR001446, and TL1TR001447; American Heart Association Career Development Grant 18CDA34080540; Dermatology Foundation Research Grant; and National Psoriasis Foundation Bridge Grant (all awarded to MSG) and American Heart Association Career Development Grant 18CDA34110203AHA and American Society of Hematology (18-A0-00-1001884) to TJB. JUS was supported, in part, by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases R01AR074500, the Riley Family Foundation, the Beatriz Snyder Foundation, the Rheumatology Research Foundation , and the National Psoriasis Foundation Diagnostic Challenge Grant. JSB was supported, in part, by the National Institutes of Health grants R01HL139909 and R35HL144993. Funding Information: MSG has received personal fees from Abbvie. JUS has served as a consultant for Janssen, Abbvie, Novartis, Sanofi, UCB, and BMS. JK has received grants from Novartis, Pfizer, Amgen, Lilly, Boehringer, Innovaderm, BMS, Janssen, Abbvie, Paraxel, Leo Pharma, Vitae, Akros, Regeneron, Allergan, Novan, Biogen MA, Sienna, UCB, Celgene, Botanix, Incyte, Avillion, and Exicure. He has received personal fees from Novartis, Pfizer, Amgen, Lilly, Boehringer, BiogenIdec, Abbvie, Leo Pharma, Escalier, Valeant, Aurigne, Allergan, Asana, UCB, Sienna, Celgene, Nimbus, Menlo, Aristea, Sanofi, Sun Pharma, Almirall, Arena, and BMS. JSB has grants from the National Institutes of Health/National Heart, Lung, and Blood Institute related to the topic and has served on the advisory board for Amgen and Jannsen.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85123364970&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2021.07.190

DO - 10.1016/j.jid.2021.07.190

M3 - Article

C2 - 34808233

AN - SCOPUS:85123364970

SN - 0022-202X

VL - 142

SP - 1749-1752.e4

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 6

ER -